Profil bibliographique

Julie M. Asare

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

20Publications signalées

45Citations signalées

2Affiliations récentes

Institutions déclarées

AstraZeneca (Netherlands)AstraZeneca (Japan)

Domaines associés

Acute Lymphoblastic Leukemia researchCancer Immunotherapy and BiomarkersChildhood Cancer Survivors' Quality of LifeLymphoma Diagnosis and TreatmentLung Cancer Diagnosis and Treatment

Publications récentes

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.